MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Search

CytoSorbents Corp

Closed

SectorHealthcare

0.66

Overview

Share price change

24h

Current

Min

0.64

Max

0.67

Key metrics

By Trading Economics

Income

-5.1M

-3.2M

Sales

-132K

9.5M

EPS

-0.05

Profit margin

-33.421

Employees

149

EBITDA

-5.9M

-2.9M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+11.94% upside

Dividends

By Dow Jones

Next Earnings

24 mar 2026

Market Stats

By TradingEconomics

Market Cap

-3.5M

42M

Previous open

0.66

Previous close

0.66

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

CytoSorbents Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 sty 2026, 22:18 UTC

Market Talk

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9 sty 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 sty 2026, 21:43 UTC

Earnings
Acquisitions, Mergers, Takeovers

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 sty 2026, 20:39 UTC

Market Talk

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 sty 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 sty 2026, 20:36 UTC

Acquisitions, Mergers, Takeovers

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 sty 2026, 20:30 UTC

Market Talk

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 sty 2026, 20:15 UTC

Market Talk

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 sty 2026, 20:07 UTC

Market Talk

Global Equities Roundup: Market Talk

9 sty 2026, 20:07 UTC

Market Talk

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 sty 2026, 19:58 UTC

Acquisitions, Mergers, Takeovers

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 sty 2026, 19:42 UTC

Market Talk

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 sty 2026, 19:38 UTC

Acquisitions, Mergers, Takeovers

Wolters Kluwer Acquires StandardFusion >WTKWY

9 sty 2026, 19:31 UTC

Earnings

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 sty 2026, 19:28 UTC

Earnings

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 sty 2026, 18:30 UTC

Market Talk

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 sty 2026, 18:23 UTC

Market Talk

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 sty 2026, 17:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

9 sty 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 sty 2026, 17:19 UTC

Market Talk

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9 sty 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 sty 2026, 17:07 UTC

Market Talk

McDonald's Promotions Appear Successful -- Market Talk

9 sty 2026, 17:06 UTC

Market Talk

Oil Futures on Track for Weekly Gains -- Market Talk

9 sty 2026, 17:05 UTC

Earnings

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

9 sty 2026, 16:57 UTC

Market Talk

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

9 sty 2026, 16:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 sty 2026, 16:46 UTC

Market Talk

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Peer Comparison

Price change

CytoSorbents Corp Forecast

Price Target

By TipRanks

11.94% upside

12 Months Forecast

Average 0.75 USD  11.94%

High 0.75 USD

Low 0.75 USD

Based on 1 Wall Street analysts offering 12 month price targets forCytoSorbents Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

0

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

0.705 / 0.771Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
help-icon Live chat